Cargando…

Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban

BACKGROUND: Novel biomarkers for personalizing anticoagulation remain undetermined. We aimed to investigate the association of plasma miRNAs with pharmacokinetic–pharmacodynamic (PK-PD) profiles of rivaroxaban. METHODS: This is a multicenter, exploratory study of miRNAs in a Chinese population. Heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hanxu, Zhang, Zhuo, Liu, Zhiyan, Mu, Guangyan, Xie, Qiufen, Zhou, Shuang, Wang, Zhe, Cao, Yu, Tan, Yunlong, Wei, Xiaohua, Yuan, Dongdong, Xiang, Qian, Cui, Yimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795792/
https://www.ncbi.nlm.nih.gov/pubmed/36578040
http://dx.doi.org/10.1186/s40246-022-00445-5
_version_ 1784860336039395328
author Zhang, Hanxu
Zhang, Zhuo
Liu, Zhiyan
Mu, Guangyan
Xie, Qiufen
Zhou, Shuang
Wang, Zhe
Cao, Yu
Tan, Yunlong
Wei, Xiaohua
Yuan, Dongdong
Xiang, Qian
Cui, Yimin
author_facet Zhang, Hanxu
Zhang, Zhuo
Liu, Zhiyan
Mu, Guangyan
Xie, Qiufen
Zhou, Shuang
Wang, Zhe
Cao, Yu
Tan, Yunlong
Wei, Xiaohua
Yuan, Dongdong
Xiang, Qian
Cui, Yimin
author_sort Zhang, Hanxu
collection PubMed
description BACKGROUND: Novel biomarkers for personalizing anticoagulation remain undetermined. We aimed to investigate the association of plasma miRNAs with pharmacokinetic–pharmacodynamic (PK-PD) profiles of rivaroxaban. METHODS: This is a multicenter, exploratory study of miRNAs in a Chinese population. Healthy volunteers and patients receiving rivaroxaban were enrolled in the study. The area under the plasma concentration–time curve from time 0-t h (AUC(0-t)) and anti-Xa activity at 3 h (AXA(3h)) were measured in healthy volunteers, and AXA(3h) was measured in patients. MiRNAs were detected by miRNA microarray in 26 healthy volunteers with 20 mg rivaroxaban, and quantitative reverse transcription polymerase chain reaction was used to exclude undetectable ones. MiR-320a-3p and miR-483-5p were then quantified in 65 healthy volunteers and 71 patients. MiRNA levels at 3 h were compared between high and low AXA(3h) or AUC(0-t) subjects and in matched patients with or without bleeding during follow-up. The miRNA targets were predicted by TargetScan, miRTarBase, and miRDB. Validated genes were included in GO enrichment and KEGG analyses. The protein–protein interaction network was established by STRING and visualized by Cytoscape. RESULTS: A total of 136 Chinese subjects completed the study. In healthy volunteers taking 15 mg rivaroxaban, the miR-320a level at 3 h was significantly positively correlated with AXA(3h) and AUC(0-t) (r = 0.359, p = 0.025; r = 0.370, p = 0.02, respectively). A positive correlation was also observed between miR-483 and AXA(3h) or AUC(0-t) (r = 0.372, p = 0.02; r = 0.523, p = 0.001, respectively). MiR-320a and miR-483 levels at 3 h in the higher AUC(0-t) group were significantly higher than those at 0 h. MiR-483 levels at 3 h may distinguish healthy volunteers with high or low AXA(3h) or AUC(0-t). In the 10 mg fed subgroup, higher 3 h mir-483 levels were also observed compared with the control group. No significant differences were found in the comparisons among patients. Bioinformatic analysis showed that these miRNAs may play a regulatory role by targeting ABCG2, ITGB3, PTEN, MAPK1/3, etc. CONCLUSIONS: MiR-320a and miR-483 levels were found to be associated with PK and PD profiles of rivaroxaban in healthy Chinese subjects. Further studies are required to verify these findings and explore the mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40246-022-00445-5.
format Online
Article
Text
id pubmed-9795792
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97957922022-12-29 Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban Zhang, Hanxu Zhang, Zhuo Liu, Zhiyan Mu, Guangyan Xie, Qiufen Zhou, Shuang Wang, Zhe Cao, Yu Tan, Yunlong Wei, Xiaohua Yuan, Dongdong Xiang, Qian Cui, Yimin Hum Genomics Research BACKGROUND: Novel biomarkers for personalizing anticoagulation remain undetermined. We aimed to investigate the association of plasma miRNAs with pharmacokinetic–pharmacodynamic (PK-PD) profiles of rivaroxaban. METHODS: This is a multicenter, exploratory study of miRNAs in a Chinese population. Healthy volunteers and patients receiving rivaroxaban were enrolled in the study. The area under the plasma concentration–time curve from time 0-t h (AUC(0-t)) and anti-Xa activity at 3 h (AXA(3h)) were measured in healthy volunteers, and AXA(3h) was measured in patients. MiRNAs were detected by miRNA microarray in 26 healthy volunteers with 20 mg rivaroxaban, and quantitative reverse transcription polymerase chain reaction was used to exclude undetectable ones. MiR-320a-3p and miR-483-5p were then quantified in 65 healthy volunteers and 71 patients. MiRNA levels at 3 h were compared between high and low AXA(3h) or AUC(0-t) subjects and in matched patients with or without bleeding during follow-up. The miRNA targets were predicted by TargetScan, miRTarBase, and miRDB. Validated genes were included in GO enrichment and KEGG analyses. The protein–protein interaction network was established by STRING and visualized by Cytoscape. RESULTS: A total of 136 Chinese subjects completed the study. In healthy volunteers taking 15 mg rivaroxaban, the miR-320a level at 3 h was significantly positively correlated with AXA(3h) and AUC(0-t) (r = 0.359, p = 0.025; r = 0.370, p = 0.02, respectively). A positive correlation was also observed between miR-483 and AXA(3h) or AUC(0-t) (r = 0.372, p = 0.02; r = 0.523, p = 0.001, respectively). MiR-320a and miR-483 levels at 3 h in the higher AUC(0-t) group were significantly higher than those at 0 h. MiR-483 levels at 3 h may distinguish healthy volunteers with high or low AXA(3h) or AUC(0-t). In the 10 mg fed subgroup, higher 3 h mir-483 levels were also observed compared with the control group. No significant differences were found in the comparisons among patients. Bioinformatic analysis showed that these miRNAs may play a regulatory role by targeting ABCG2, ITGB3, PTEN, MAPK1/3, etc. CONCLUSIONS: MiR-320a and miR-483 levels were found to be associated with PK and PD profiles of rivaroxaban in healthy Chinese subjects. Further studies are required to verify these findings and explore the mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40246-022-00445-5. BioMed Central 2022-12-28 /pmc/articles/PMC9795792/ /pubmed/36578040 http://dx.doi.org/10.1186/s40246-022-00445-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Hanxu
Zhang, Zhuo
Liu, Zhiyan
Mu, Guangyan
Xie, Qiufen
Zhou, Shuang
Wang, Zhe
Cao, Yu
Tan, Yunlong
Wei, Xiaohua
Yuan, Dongdong
Xiang, Qian
Cui, Yimin
Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
title Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
title_full Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
title_fullStr Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
title_full_unstemmed Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
title_short Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
title_sort circulating mir-320a-3p and mir-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795792/
https://www.ncbi.nlm.nih.gov/pubmed/36578040
http://dx.doi.org/10.1186/s40246-022-00445-5
work_keys_str_mv AT zhanghanxu circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT zhangzhuo circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT liuzhiyan circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT muguangyan circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT xieqiufen circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT zhoushuang circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT wangzhe circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT caoyu circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT tanyunlong circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT weixiaohua circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT yuandongdong circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT xiangqian circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban
AT cuiyimin circulatingmir320a3pandmir4835plevelassociatedwithpharmacokineticpharmacodynamicprofilesofrivaroxaban